{"schema_version":"secwatch.filing_event.v1","accession":"0001159036-25-000008","form_type":"8-K","ticker":"HALO","cik":"0001159036","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2025-02-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.054646+00:00","generated_at":"2026-05-26T14:23:51.441473+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Halozyme reports record 2024 revenue of $1.015B, Q4 net income up 60% YoY","bullets":["Q4 total revenue $298M (+30% YoY); royalty revenue $170M (+40% YoY).","Q4 GAAP EPS $1.06 (+63% YoY); non-GAAP EPS $1.26 (+54% YoY).","Full-year 2024 total revenue $1,015M (+22% YoY); net income $444M (+58% YoY).","Full-year adjusted EBITDA $632M (+48% YoY), exceeding guidance.","Reiterates 2025 guidance: total revenue $1,150-1,225M, non-GAAP EPS $4.95-5.35."],"urls":{"canonical":"https://secwatch.observer/filing/0001159036-25-000008","json":"https://secwatch.observer/filing/0001159036-25-000008.json","markdown":"https://secwatch.observer/filing/0001159036-25-000008.md","text":"https://secwatch.observer/filing/0001159036-25-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1159036/000115903625000008/0001159036-25-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1159036/000115903625000008/halo-20250218.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T14:23:51.441473+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}